Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial-Reference-Cited by-同舟云学术

Benefit of continuous treatment for responders with newly diagnosed multiple myeloma in the randomized FIRST trial

Published:2017-04-04 Issue:11 Volume:31 Page:2435-2442
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Bahlis N J,Corso A,Mugge L-O,Shen Z-X,Desjardins P,Stoppa A-M,Decaux O,de Revel T,Granell M,Marit G,Nahi H,Demuynck H,Huang S-Y,Basu S,Guthrie T H,Ervin-Haynes A,Marek J,Chen G,Facon T

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2017111.pdf

Reference22 articles.

1. San Miguel J, Mateos M . Advances in treatment for newly diagnosed multiple myeloma patients ineligible for autologous stem cell transplantation. Leukemia Supp 2013; 2: S21–S27.

2. Palumbo A, Mina R . Part II: role of maintenance therapy in transplant-ineligible patients. J Natl Compr Canc Netw 2013; 11: 43–49.

3. Hoering A, Crowley J, Shaughnessy Jr JD, Hollmig K, Alsayed Y, Szymonifka J et al. Complete remission in multiple myeloma examined as time-dependent variable in terms of both onset and duration in total therapy protocols. Blood 2009; 114: 1299–1305.

4. Barlogie B, Anaissie E, Haessler J, van Rhee F, Pineda-Roman M, Hollmig K et al. Complete remission sustained 3 years from treatment initiation is a powerful surrogate for extended survival in multiple myeloma. Cancer 2008; 113: 355–359.

5. Romano A, Conticello C, Cavalli M, Vetro C, Di Raimondo C, Di Martina V et al. Salvage therapy of multiple myeloma: the new generation drugs. Biomed Res Int 2014; 2014: 456037.

Cited by 19 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Lenalidomide or Thalidomide for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma? An Overview of Systematic Reviews;Value in Health Regional Issues;2024-09

2. Predictors of Lenalidomide Refractory Relapse Timing With Newly Diagnosed Multiple Myeloma: A FIRST Trial Subanalysis;Clinical Lymphoma Myeloma and Leukemia;2023-09

3. How to Manage Patients with Lenalidomide-Refractory Multiple Myeloma;Cancers;2022-12-27

4. Front‐line treatment efficacy and clinical outcomes of elderly patients with multiple myeloma in a real‐world setting: A multicenter retrospective study in China;Cancer Medicine;2022-10-21

5. Healthcare Resource Utilization and Cost of Patients with Multiple Myeloma in Germany: A Retrospective Claims Data Analysis;PharmacoEconomics - Open;2022-06-24